Pharmaceutical company to begin trials of UK vaccine from 16 November.
Global pharmaceutical company Janssen will begin clinical trials of its potential vaccine in the UK from today (Monday 16 November), involving 6,000 volunteers across the country.
The Janssen Pharmaceutical Companies, part of Johnson & Johnson, is the latest study in the UK, jointly funded by the UK government’s Vaccine Taskforce, to test the safety and effectiveness of a potential Covid-19 vaccine. It is the third potential vaccine to enter clinical trials in the UK, alongside US biotech company Novavax and University of Oxford / AstraZeneca whose studies are currently ongoing.
6,000 UK volunteers, some from the NHS Vaccines Registry, will take part in the Janssen studies at 17 National Institute for Health Research (NIHR) sites, including in Southampton, Bristol, Cardiff, London Leicester, Sheffield, Manchester, Dundee and Belfast. Recruitment into the study will complete in March 2021 and the trial will last for 12 months.
To date, over 300,000 people have signed up to the NHS Vaccines Registry to take part in vital coronavirus vaccine studies.
Experts have cautioned that no one vaccine is likely to be suited for everyone, and that a wide range of types are needed to ensure people across the UK have access to one that works for them, so they are urging more people to sign-up to ensure clinical trials that test the safety and effectiveness of potential vaccine candidates continue. The NHS vaccine registry particularly needs volunteers who are most vulnerable to the effects of coronavirus, including frontline health and social care workers and people from Black, Asian and ethnic minority backgrounds.
Business Secretary, Alok Sharma, said:
The UK Government has developed a portfolio of six different vaccine candidates and secured access to 350 million doses to date, putting the UK in the best position for a vaccine. Of this, 30 million doses of the Janssen vaccine could be made available to the UK if it is safe and effective by mid-2021.
Professor Saul Faust, Director of the NIHR Southampton Clinical Research Facility and Chief Investigator for the Janssen Phase 3 trial, said:
Chair of the Government’s Vaccine Taskforce, Kate Bingham said:
Black, Asian and minority ethnic Clinical Champion at NIHR Clinical Research Network North Thames, and consultant in Sexual Health and HIV at Barts Health NHS Trust, Dr Vanessa Apea, said:
Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson said:
The UK public can support the national effort to speed up vaccine research and receive more information about volunteering for clinical studies by visiting this page to join the NHS Vaccine Research Registry.
The Registry was launched by the UK government in partnership with the NIHR, NHS Digital, the Scottish and Welsh governments and the Northern Ireland Executive in July. It aims to help create a database of people who consent to be contacted by the NHS to take part in clinical studies, to help speed up the development of a safe and effective vaccine.
Janssen’s phase three clinical trials will involve 30,000 people worldwide.
Volunteering for COVID-19 vaccine clinical trials:
People wishing to volunteer to support clinical trials can sign up for information on Covid-19 vaccine trials with the NHS Covid-19 vaccine research registry, developed in partnership with NHS Digital. It is helping large numbers of people to be recruited into trials rapidly over the coming months – potentially meaning an effective vaccine for coronavirus can be found as soon as possible.
The service was commissioned as part of the UK Government’s Vaccine Taskforce in conjunction with the National Institute for Health Research (NIHR) and the Northern Ireland, Scottish and Welsh Governments.
Anyone living in the UK can sign up online to take part in the trials through the NHS, giving permission for researchers to contact you if they think you’re a good fit. Once you sign up, you can withdraw at any time and request that your details be removed from the COVID-19 vaccine research registry. The process takes about 5 minutes to complete. More information can be found here.